2022
Durable functional limitation in patients with coronavirus disease-2019 admitted to intensive care and the effect of intermediate-dose vs standard-dose anticoagulation on functional outcomes
INVESTIGATORS I, Sadeghipour P, Talasaz A, Barco S, Bakhshandeh H, Rashidi F, Rafiee F, Rezaeifar P, Jamalkhani S, Matin S, Baghizadeh E, Tahamtan O, Sharif-Kashani B, Beigmohammadi M, Farrokhpour M, Sezavar S, Payandemehr P, Dabbagh A, Moghadam K, Jimenez D, Monreal M, Maleki M, Siegerink B, Spatz E, Piazza G, Parikh S, Kirtane A, Van Tassell B, Lip G, Goldhaber S, Klok F, Krumholz H, Bikdeli B. Durable functional limitation in patients with coronavirus disease-2019 admitted to intensive care and the effect of intermediate-dose vs standard-dose anticoagulation on functional outcomes. European Journal Of Internal Medicine 2022, 103: 76-83. PMID: 35879217, PMCID: PMC9212871, DOI: 10.1016/j.ejim.2022.06.014.Peer-Reviewed Original ResearchMeSH KeywordsAnticoagulantsCOVID-19Critical CareFemaleHospitalizationHumansMaleMiddle AgedSARS-CoV-2ConceptsStandard-dose prophylactic anticoagulationPatient Health Questionnaire-2Proportion of patientsProphylactic anticoagulationIntermediate doseFunctional limitationsDepressive symptomsFunctional outcomeCOVID-19Intensive care unit hospitalizationCritically Ill PatientsMultiple organ failureSevere functional limitationsFunctional Status ScaleCoronavirus disease 2019Open labelExercise limitationAirway diseaseICU patientsOrgan failureIntensive careStatus ScaleClinical trialsGrade 3Anticoagulation
2018
Variation in the Use of Warfarin and Direct Oral Anticoagulants in Atrial Fibrillation and Associated Cost Implications
Rodwin BA, Salami JA, Spatz ES, Valero-Elizondo J, Virani SS, Blankstein R, Blaha MJ, Nasir K, Desai NR. Variation in the Use of Warfarin and Direct Oral Anticoagulants in Atrial Fibrillation and Associated Cost Implications. The American Journal Of Medicine 2018, 132: 61-70.e1. PMID: 30290193, DOI: 10.1016/j.amjmed.2018.09.026.Peer-Reviewed Original ResearchConceptsDirect oral anticoagulantsUse of DOACsAtrial fibrillationOral anticoagulantsDiseases Ninth Edition (ICD-9) codesPocket costsProportion of patientsUse of warfarinNinth Edition codesMedical Expenditure Panel SurveyPrescription drug useTotal drug expendituresPrescription drug spendingWarfarin useAnticoagulant useNationwide cohortClinical factorsMedication useEdition codesStudy populationInternational ClassificationDrug useFibrillationClinical groupsAnticoagulants